Paxalisib: Beyond glioblastoma and commercial opportunity

Published on 10 May 2022

In the second part of this three-episode Edison TV series, Kazia Therapeutics (KZIA), dives deeper into paxalisib for additional indications beyond glioblastoma. These indications include DIPG, a highly aggressive childhood brain cancer, primary CNS lymphoma, and brain metastases.

John Friend, CMO, discusses ongoing investigator-initiated trials and collaborations. James Garner, CEO, addresses commercialisation plans.

Share this with friends and colleagues